PMID- 24811396
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 48
IP  - 8
DP  - 2014 Aug
TI  - Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C 
      Infection.
PG  - 1019-1029
AB  - OBJECTIVE: To review the use of sofosbuvir for the treatment of chronic hepatitis 
      C virus (HCV). DATA SOURCES: Review and nonreview articles were identified 
      through MEDLINE (1996-April 2014), citations of articles, and meeting abstracts 
      using keywords, including NS5B polymerase inhibitor, GS-7977, sofosbuvir, 
      direct-acting antiviral (DAA), and others. STUDY SELECTION AND DATA EXTRACTION: 
      Phase 1, 2, and 3 studies describing dose-ranging potential, pharmacokinetics, 
      efficacy, safety, and tolerability of sofosbuvir were identified. DATA SYNTHESIS: 
      Sofosbuvir is an NS5B polymerase inhibitor that was approved for use by the Food 
      and Drug Administration in December 2013 for the treatment of chronic HCV in 
      combination with pegylated interferon (peg-IFN) and ribavirin (RBV) for genotype 
      1. Additionally, it has been evaluated with other oral DAAs, such as simeprevir 
      and others in the pipeline. It is not recommended as monotherapy because of lower 
      sustained virological response (SVR) rates in clinical studies. Most of the 
      treatment regimens are 12 weeks in duration; however, certain populations require 
      a longer duration. Sofosbuvir has activity against all 6 genotypes, although most 
      clinical trials evaluated genotypes 1 to 3. Sofosbuvir has a favorable safety and 
      tolerability profile, making it a recommended first-line agent for chronic HCV 
      infection. CONCLUSION: In clinical trials, 12 weeks of sofosbuvir with 
      concomitant peg-IFN and RBV therapy in treatment-naive and experienced HCV 
      genotype 1 patients resulted in SVR rates of >90%. An all-oral regimen of 
      sofosbuvir and RBV is highly effective for genotype 2 and 3 patients. Sofosbuvir 
      was found to be tolerable with minimal adverse effects (AEs), and no treatment 
      discontinuations occurred secondary to drug related AEs..
CI  - (c) The Author(s) 2014.
FAU - Rose, Lucia
AU  - Rose L
AD  - Western New England University, Springfield, MA, USA lrose@wne.edu.
FAU - Bias, Tiffany E
AU  - Bias TE
AD  - Hahnemann University Hospital, Philadelphia, PA, USA.
FAU - Mathias, Clinton B
AU  - Mathias CB
AD  - Western New England University, Springfield, MA, USA.
FAU - Trooskin, Stacey B
AU  - Trooskin SB
AD  - Drexel University College of Medicine, Philadelphia, PA, USA.
FAU - Fong, Jeffrey J
AU  - Fong JJ
AD  - MCPHS University-Worcester/Manchester, Worcester, MA, USA.
LA  - eng
PT  - Review
DEP - 20140508
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
OTO - NOTNLM
OT  - GS-7977
OT  - NS5B polymerase inhibitor
OT  - chronic hepatitis C infection
OT  - sofosbuvir
EDAT- 2014/05/09 06:00
MHDA- 2014/05/09 06:00
CRDT- 2014/05/10 06:00
PHST- 2014/05/10 06:00 [entrez]
PHST- 2014/05/09 06:00 [pubmed]
PHST- 2014/05/09 06:00 [medline]
AID - 1060028014534194 [pii]
AID - 10.1177/1060028014534194 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2014 Aug;48(8):1019-1029. doi: 10.1177/1060028014534194. Epub 
      2014 May 8.